Product Description
Acumapimod is a potent, selective, oral, p38 inhibitor under investigation for treatment of acute exacerbations of COPD (AECOPD).
Mechanisms of Action: MAP2K Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Mereo BioPharma
Company Location: LONDON X0 W1G0QF
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Chronic Obstructive Pulmonary Disease|Acute Kidney Injury
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MBCT103 | P1 |
Completed |
Healthy Volunteers |
2018-05-03 |
|
| MBCT206 | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2017-11-08 |
|
| 2015-004631-13 | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2017-11-07 |
|
| MBCT102 | P1 |
Completed |
Healthy Volunteers |
2016-10-01 |